Today’s AI Top Pick: PODD

7/8/2026 · Recently Alerted GARP screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Recently Alerted GARPPODDBUY NOW8.6 / 107/8/2026

Insulet (PODD) is the cleanest combination of strong fundamentals, multi-timeframe forecast agreement, and a bona fide product catalyst. On the tape, the 4h/1d/1wk forecasts all point sharply higher — fc_mid 59.14%/64.45%/62.77% and fc_long 86.40%/51.19%/76.03% — with bullish_prob 1.0 and near_term_bullish 0.8. Critically, while 1d position-in-range is elevated at 91.06%, the 1wk read is only 16.98% with a −34.23% weekly drawdown, meaning the daily rally is happening off a deeply washed-out weekly base, not from all-time highs. That's the ideal structure: buyers stepping in early after a big weekly reset. Fundamentals are best-in-class: fwdPe 20, PEG 0.74, epsNextY 24.63%, salesYoY 31.93%, profitMargin 10.44%, ROE 23%, grossMargin 71.64%, and analyst recom 1.43 with 46.3% target upside. This isn't a story stock — it's a profitable, high-growth diabetes tech franchise trading well below its 52-week high. The news backdrop is a clear tailwind, not a landmine: Deutsche Bank initiated Buy with a $190 target (7/6), Omnipod 5 launched in Spain (7/7 — TAM expansion), and Zacks flagged another earnings beat setup (7/7). None of the recent headlines contain guidance cuts, legal risk, dilution, or short-seller drama — a stark contrast to FUTU (DOJ probe/class actions) and CALX (class action deadline). Why today vs. wait? The daily forecast fc_short 12.46% suggests momentum continues near-term, and buying the first pullback into the $155–160 shelf gives an asymmetric entry into a name with 50%+ modeled mid-term upside and a hard analyst target of $190. Waiting risks missing the pre-earnings run.

Entry zone

$158–$162 (buy half here at $162.20, add on a dip to $158)

Stop loss

$148 (below the recent daily consolidation and ~9% risk)

First target

$185–$190 (Deutsche Bank PT, ~17% upside)

Longer target

$215–$225 (aligns with 1wk fc_long +76% off the recent base; ~35–40% upside)

Risks

1d position-in-range at 91.06% means a near-term pullback of 3–5% is plausible before continuation
Medtech competitive risk (Tandem, Medtronic 780G) could compress the Omnipod 5 pricing runway
Short float 7.11% is moderate but earnings misses in this group get punished hard
1wk drawdown of −34.23% means the weekly downtrend is only just turning — a break of $148 invalidates the reversal
Broader risk-off: macro headlines (Iran, Fed 'family fight' on rates) could pressure high-multiple healthcare growth

Honorable mentions

ORCLDeep-value oversold reversal: RSI 29.17, 1d pos-in-range 0% (max pain), −34.18% daily drawdown, yet fc_mid +32.5% and fc_long +32.74% on 1d with bullish_prob 1.0. Best-in-class quality (operMargin 33.3%, profitMargin 25.2%), fwdPe 12.98, PEG 0.49, and positive news ('Cloud Revenue Could Beat FY27'). The classic 'buy quality when it's hated' setup.

HSAIHesai has strong multi-tf forecast alignment (1d fc_short 38.4%, fc_mid 32.5%, fc_long 44.7%) with pos-in-range only 30.96% on 1d and 10.42% on 1wk — not chased. Explosive growth (salesYoY 44.14%, epsNextY 68.61%), PEG 0.43, recom 1.27, target upside 85.9%. Lidar demand story intact per recent notes.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.6	Multi-tf forecasts +51–86%, weekly base still low (pos 16.98%), Deutsche Bank Buy $190, Omnipod 5 Spain launch.
2	ORCL	BUY NOW	8.1	RSI 29, 1d pos 0%, −34% drawdown with fc_mid/long +32%; quality reversal in a fwdPe 13 mega-cap.
3	HSAI	BUY NOW	7.8	Mid-range entry (1d pos 30.96%) with fc_long +44.73% and 44% sales growth; not chased.
4	ADMA	BUY PULLBACK	7.5	Fantastic forecasts (fc_long 73.23% 1d) but 1d pos 92.17% — wait for a dip to $8.50.
5	NAGE	BUY PULLBACK	7.1	1d fc_short +92.7%, recom 1.00, but 1wk forecasts negative and micro-cap illiquidity risk.
6	MLCO	BUY NOW	6.9	PEG 0.23, 1wk fc_mid +51%, pos-in-range low across all TFs; Morgan Stanley downgrade already digested.
7	UWMC	BUY PULLBACK	6.7	Extreme forecasts (fc_mid +94% 1d, +148% 1wk) but debtEq 70.65 is a landmine — size small.
8	PDD	BUY PULLBACK	6.6	Strong fc_mid/long +19.96/24.66% 1d but sitting at 1d pos 100% — chase risk.
9	SE	BUY PULLBACK	6.5	1wk fc_mid +52.6% and analyst upgrades, but 1d pos 80.5% and RSI 67.7 — wait for pullback.
10	BILI	BUY PULLBACK	6.4	1wk fc_mid +103% and $300M buyback catalyst, but 4h pos 100% — buy the dip.
11	SMCI	BUY PULLBACK	6.1	1d pos 0% with fc_mid +45% but recom 3.0 (hold) and 36% one-month collapse — wait for base.
12	INTR	BUY PULLBACK	6.0	1d fc_short +38.1% and PEG 0.24, but 1wk forecasts negative and weekly pos 2.36%.
13	CALX	BUY PULLBACK	5.9	1d fc_short +25.74% but 1d pos 91.98% and class-action headline — chase risk.
14	HURN	BUY NOW	5.9	1d fc_mid +22.7%, near_term_bullish 1.0, recom 1.00; smaller size but clean setup.
15	SRAD	WAIT	5.6	1wk forecasts negative (−21.7% mid, −11.3% long) undermine daily strength.
16	PFSI	WAIT	5.4	Solid forecasts but Barclays downgrade today is a fresh negative catalyst.
17	BX	WAIT	5.3	Modest forecasts (1wk fc_long +8.4%) and stretched valuation (PS 9.93).
18	ONON	WAIT	5.2	Bland forecasts (1d fc_mid +22.4%, 1wk fc_short +3.5%); no urgency.
19	CELH	WAIT	5.1	Strong 1d fc_mid +41% but short float 20.7% and fwd growth vs. peer competition worries.
20	MSFT	WAIT	5.0	Near_term_bullish only 0.2, 1wk fc_long +0.77% — no edge here today.
21	BILL	WAIT	4.9	PE null, operMargin −2.94%, short float 14.1%; wait for profitability turn.
22	FRSH	WAIT	4.7	Negative 1h fc_mid −13.9% and mid-tf weakness; wait for consolidation.
23	DCBO	WAIT	4.6	1d pos 100%, near_term_bullish 0 — completely chased into recent range.
24	TOST	AVOID	4.4	RSI 69.93, 1d pos 94%, negative long-horizon forecasts — sell-the-rip zone.
25	CEG	WAIT	4.3	52-week low headline; wait for base to form despite Walmart nuclear PPA news.
26	HNI	AVOID	3.9	PE 94.8, profitMargin 0.04%, 1h fc_mid −24.98% and negative long fc — screener false positive.
27	AGI	AVOID	3.7	1wk fc_mid −36.89% and fc_long −21.36% with analyst PT cuts — clearly broken tape.
28	ITRG	WAIT	3.5	Micro-cap with limited liquidity; Roth Buy noted but tape data absent from set.
29	RLX	WAIT	3.5	Insufficient forecast signal in provided set; screener-only conviction.
30	FUTU	AVOID	2.8	DOJ probe and US class actions (7/3) are a hard veto regardless of screen fit.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord